Marker Therapeutics (NASDAQ:MRKR) Upgraded by Brookline Capital Management to Strong-Buy Rating

Brookline Capital Management upgraded shares of Marker Therapeutics (NASDAQ:MRKR) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Separately, LADENBURG THALM/SH SH lifted their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Stock Down 9.9 %

NASDAQ:MRKR opened at $1.55 on Monday. The stock has a 50 day moving average price of $2.92 and a 200 day moving average price of $3.25. Marker Therapeutics has a one year low of $1.55 and a one year high of $5.99.

Insider Buying and Selling

In other news, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the transaction, the insider now directly owns 1,625,678 shares in the company, valued at approximately $5,202,169.60. This represents a 51.73 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steve Elms acquired 11,085 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the acquisition, the director now directly owns 325,370 shares in the company, valued at approximately $1,041,184. This trade represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. LPL Financial LLC purchased a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 79,730 shares of the company’s stock, valued at approximately $248,000. LPL Financial LLC owned 0.74% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.